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Abstract
Spinal cord injury is one of the leading causes of disability worldwide. Current 
mainstay treatment strategies consist of surgical and medical management in acute 
and subacute stage. Rehabilitative management in the chronic stage. None of the 
existing strategies can repair the damage to the spinal cord and recover neurological 
functioning. Stem cells have promising results in pre-clinical and clinical studies. 
Various pre-clinical studies have evidenced neuro-regenerative capabilities of stem 
cells and shown neural recovery. Clinical studies have also shown improvements 
in neurological functions and quality of life. This chapter discusses about different 
types of cells available, routes of administration available to transplant these cells, 
dosages of cell and optimum time after injury at which cells should be transplanted 
based on world-wide literature. We have also discussed results following our pro-
tocol of intrathecal transplantation of autologous bone marrow mononuclear cells. 
Although, not a cure, stem cell therapy further improves quality of life, functional 
independence and reduces secondary complications when combined with existing 
treatment strategies; neuroregenerative rehabilitative therapy.
Keywords: stem cell therapy, autologous, bone marrow mononuclear cells,  
spinal cord injury, paracrine effect, neurorestoration
1. Introduction
Spinal cord injury (SCI) is a disabling neurologic disorder that can lead to motor 
and sensory impairment causing, paraplegia or tetraplegia. It can also exhibit blad-
der and bowel impairment, respiratory impairment and autonomic dysfunction [1].
The incidence of the disease is estimated to be 223–755 per million worldwide [2, 3]. 
The healing and recovery process during different phases since the time of injury differ 
significantly [4].
Current treatment options consist of surgical management complimented by 
administration of methylprednisolone in the acute stage; prevention of secondary 
injury in the sub-acute stage and multidisciplinary rehabilitation management in 
the chronic stage. Due to insufficient neuroregenerative capabilities of these treat-
ments, they fail to reverse the damage to neurons and symptoms of neurological 
deficit [5–8]. Therefore, there is an unmet medical need which warrants exploring 
novel neurorestorative strategies.
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Stem cell therapy has emerged as a promising regimen to bring about neuro-
regeneration and neural functional benefits, hence can be termed as neuroregen-
erative therapy. Various cell types being explored for their effectiveness are bone 
mesenchymal stem cells (BMSCs), bone marrow mononuclear cells (BMMNCs), 
umbilical cord-derived mesenchymal stem cells (UCMSCs), adipose-derived stem 
cells (ADSCs), olfactory ensheathing cells (OECs), and fetal brain-derived neural 
stem/progenitor cell (FB-DNS/PCs), induced pluripotent stem cells (iPSCs) and 
others [9–12].
The earliest attempt in translational research were by Geron Corporation who 
had announced a clinical trial using human embryonic stem cell (ESC)-derived 
oligodendrocyte progenitor cells (OPCs) in patients with spinal cord injury at 
the site of the lesion [13]. Due to ethical and safety risks involved in ESC they 
were not widely accepted for clinical use. Advent of knowledge of the role of 
adult stem cells in natural repair processes of the body lead to clinical explora-
tion of these cells. Some of the earliest published work was by Geffner et al. 
in 2008, by transplantation of adult bone marrow stem cells through multiple 
routes, that is, intraspinal, intrathecal and intravenous in patients with SCI [14]. 
The study demonstrated that these cells and routes were safe and feasible. Many 
adult stem cell types, routes and clinical protocols have since been tested clini-
cally [14–33].
Clinical outcome and effectiveness of cell transplantation remains variable 
due to the heterogenicity of cell types, dosages, route of transplantation, level of 
manipulation and treatment regimens followed thereafter. This chapter pro-
vides a detail review about different stem cell therapies available for the man-
agement of spinal cord injury and their clinical outcomes as seen in published 
literature.
2. What are stem cells?
Stem cell is an undifferentiated cell, which can self-renew to replicate itself as 
well as give rise to the specialized cells under appropriate conditions [34].
Stem cells are the undifferentiated cells that can give rise to progeny identical 
to themselves (de-differentiation) or specialized cells different from them (trans-
differentiation). All regenerative processes in the human body during developmen-
tal pre-natal stages as well as post-natal and adult stages follow these two routes. 
Recently, the technological advances have given rise to another route, reprogram-
ming cells to acquire properties of trans-differentiation [35].
Depending upon their ability to de-differentiate or transdifferentiate, the source 
of cells, processing required to harvest the cells and host in which cells are trans-
planted; the cells can be categorized into various types which are described in detail 
in the next section.
3. Types of stem cells
3.1 Based on the potency of cells
Depending upon their differentiation potential, cells are classified as unipotent, 
multipotent, pluripotent and totipotent (Figure 1).
Totipotent cells can differentiate into embryonic as well as extraembryonic and 
placental cells [36]. Pluripotent cells can differentiate into embryonic cells only. 
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These possess the property of de-differentiation as well as trans-differentiation 
into cell types of all three germ layers [36]. Cells that can be harvested after 
birth are called ‘adult stem cells’. Most of the adult stem cells are multipotent or 
unipotent. Multipotent cells possess the property of trans-differentiation into 
cells of different tissues whereas unipotent cells can only de-differentiate to create 
progeny identical to themselves or a differentiated cell type of only one specific 
tissue [37].
3.2 Based on the host in whom cells are transplanted
If the cells are harvested from and transplanted to the same person, these are 
called autologous cells; but if the cells are harvested from a host different from that 
of the recipient these are called allogenic cells.
4. Mechanism of action of stem cells in spinal cord injury
4.1 Remyelination
The immediate impact of injury to spinal cord is on the ascending and descend-
ing pathways and blood vessels in the spinal cord. Disrupted circulation leads to 
infarction of the local tissue due to hypoxia and ischemia causing neuronal loss and 
demyelination. This is clinically presented as spinal shock, systemic hypotension, 
vasospasm, ischemia, ionic imbalance and neurotransmitter accumulation [38]. 
Transplantation of cells can remyelinate damaged tissue and aid in symptom recov-
ery. Human ESC-derived OPCs transplanted into the rats with spinal cord injury 
showed enhanced remyelination and locomotor ability when transplanted in the 
sub-acute phase as opposed to chronic phase after spinal cord injury [39]. Neural 
precursor cells also showed differentiation into oligodendrocytes ensheathing the 
Figure 1. 
Different types of cells based on their potency.
Spinal Cord Injury Therapy
4
axons, these cells expressed myelin suggesting the remyelination potential of these 
cells. Rat models, both in sub-acute and chronic phase of spinal cord injury showed 
improved functional outcome. Remyelination was better in sub-acute as compared 
with chronic phase [40]. Human UCB cells transplanted 7 days after spinal cord 
injury in the rats also showed remyelination of axons improving functional out-
come [41]. Similar results were observed using adult bone marrow mononuclear 
cells [42].
4.2 Anti-inflammatory effect
Inflammation in response to the injury is both protective and damaging to the 
tissue. Secondary injury is perpetrated by uncontrolled inflammatory response pro-
inflammatory cytokine release [43–46]. Various studies have explored anti-inflam-
matory effect of MSCs, NPCs, BMMNCs, ESCs and UCB cells. Cell transplantation 
reduces the expression of pro-inflammatory cytokines TNFα, IL-4, IL-1β, IL-2, 
IL-6, IL-7, IL-12 and interferon gamma [47–50].
4.3 Neoangiogenesis
Transplanted cells have been shown to secrete various growth factors and 
stimulate the resident cells to secret these factors through their paracrine effect. 
One of the growth factors secreted is vascular endothelial growth factor (VEGF) 
which stimulates neoangiogenesis. This proangiogenic effect has been evidenced 
by increased vascularization of the lesion area in various preclinical studies 
[51–54].
4.4 Neuro-regeneration
Transplanted cells of various cells possess neurogenic potential. Cells have 
been shown to differentiate into neuronal as well as non-neuronal tissues. Axon 
sprouting is noticed in the transplanted regions. Endogenous neurogenetic 
processes are also catalyzed by the growth factors like brain-derived neurotrophic 
factor (BDNF) secreted by these cells. Synaptic pruning is also observed. These 
changes are further reinforced by the functional locomotor recovery seen post 
transplantation [55, 56].
4.5 Neurotrophic and antiapoptotic effect
Cells secret and facilitate endogenous secretion of various growth factors like 
fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), neural 
growth factor (NGF), glial cell line-derived neurotrophic factor and brain-derived 
neurotrophic factor (BDNF). These wield neurotrophic effect protecting the 
neurons from secondary injury and apoptosis (Figure 2) [54, 57].
Figure 2. 
Bone marrow aspiration.
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5. Literature review of published evidence for efficacy of stem cells
5.1 Pre-clinical
5.1.1 Human embryonic stem cells (hESCs)
These cells can be harvested from preimplantation blastocyst after immuno-
surgical removal of trophectoderm to access the inner cells mass [58]. hESCs are 
pluripotent and can differentiate into cells of ectodermal origin, that is, neuronal 
and glial cells. hESCs derived oligodendrocyte progenitor cells (OPCs) have shown 
neuronal recovery more effectively in the acute phase as compared to chronic phase 
of spinal cord injury [39, 59, 60]. Neural stem cells (NSCs) have the potential to dif-
ferentiate into neural and non-neural tissue. Neuroregenerative potential of these 
exhibited as remyelination of damaged axons and secretion of neurotrophic factors 
enhancing neuronal survival post SCI in mice [61–63].
Despite promising results in pre-clinical studies, clinical translation of these is 
limited due to ethical concerns, risk of immune rejection and tumorigenicity [64].
5.1.2 Multipotent stem cells
Adult stem cells like bone marrow stromal cells (BMSCs), mesenchymal stem 
cells (MSCs), umbilical cord stromal cells (UCSCs), umbilical cord mesenchymal 
cells (UC-MSCs), adipose-derived stem cells and dental pulp-derived stem cells are 
examples of multipotent stem cells [51]. MSCs and BMSCs are easy to harvest as 
they are available in the bone marrow. However, MSCs are available in a small num-
ber and therefore need to be expanded in-vitro before transplantation. These cells 
can migrate and home onto the site of injury therefore can be administered through 
a less invasive route distant from the site of injury. Unlike pluripotent cells, these 
cells show better functional recovery in chronic SCI [41, 42, 65]. Transplantation 
of these cells has shown functional and motor recovery in rats after SCI in several 
studies. These benefits are postulated to be due to neurotrophic, immunomodula-
tory and neoangiogenic effect of these cells in addition to their ability to differenti-
ate neural cells [66].
5.1.3 Induced pluripotent stem cells (iPSCs)
Last decade has seen rise in efforts to develop technologies to improve quality 
and efficiency of reprogramming of cells to induce pluripotency. iPSCs are also plu-
ripotent and give rise to neuronal as well as non-neuronal tissue. Transplantation of 
progenitors derived from iPSCs have shown ability for remyelination of damaged 
neurons and improved nerve conduction. These cells can migrate long distances 
and therefore can be administered at a remote site which is less invasive. Apart from 
neuroregeneration, the cells are also capable of immunomodulation and synaptic 
reconstruction [67–72].
The technology is still in its nascent stage, although promising, successful clini-
cal translation has barriers.
5.2 Clinical
5.2.1 Embryonic stem cells (ESCs)
One of the earliest studies used cells from the fetal nervous and hemopoietic 
tissues in 15 SCI patients with no side effects [73]. However, due to various ethical 
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and medical concerns the use of these cells in clinical trials and application is 
restricted worldwide.
5.2.2 Multipotent stem cells
Various studies have explored and demonstrated safety and feasibility of multi-
potent stem cells [15, 17, 74–83].
5.2.2.1 Bone marrow mononuclear cells
In a comparison between transplantation of autologous bone marrow cells 
directly into the SCI sites administered with subcutaneous injections of granu-
locyte macrophage colony stimulating factor (GM-CSF) {n = 5} and only admin-
istration of GM-CSF {n = 1}, combination group showed better improvements. 
Improvements were noted during 3–7 months post procedure, 1 patient from the 
combination group showed change in the AIS grade as well. There were mild side 
effects associated with GM-CSF administration like Fever, myalgia and leuko-
cytosis; however, there were no irreversible adverse events noted, neither was 
there any neurological deterioration [16]. Kumar et al. studied the effect of bone 
marrow mononuclear cells and noted that there was perceptible improvement 
in 32.6% of the patients with no major irreversible adverse effects. Outcome did 
not vary with the time taken from the injury till intervention [35]. Al-Zoubi et al. 
demonstrated the positive effect of purified autologous leukapheresis-derived 
CD34+ and CD133+ stem cells in 19 cases of chronic SCI [29]. Our published 
results with mononuclear cells are discussed in detail in the later part of the 
chapter [84, 85].
5.2.2.2 Mesenchymal cells
In a novel method, using combination of bone marrow mesenchymal stem 
cells (BM-MSC) and patient’s autoimmune T cells, Moviglia et al. demonstrated 
the neuro-regeneration phenomenon-based changes in the inflammatory pro-
cesses at the site of injury. Both the patients showed motor and sensory recovery 
with no adverse effects [17]. Peripheral stem cells and macrophages have also 
been reported to show improvements of motor and sensory functions without 
any adverse effects [18, 19]. Cheng et al. in a controlled study including 34 cases 
of thoracolumbar spinal cord injury, stated that umbilical cord mesenchymal 
stem cells effectively improve neurological functional recovery after spinal cord 
injury, and its efficacy is superior to that of rehabilitation therapy and self-
healing [30].
5.2.2.3 Others
Other sources such as cord blood, olfactory ensheathing cells and adipose 
tissue derived stem cells also showed improvement in sensory-motor functional 
improvements [20–24]. Saberi et al. studied the safety of intramedullary Schwann 
cell transplantation in 33 patients over the period of 2 years, there were no tumor 
formation or other adverse events recorded [25].
5.2.2.4 Co-transplantation of multiple cell types
Co-transplantation of cells has also been explored. Combined use of olfactory 
ensheathing cells and Schwann cells enhanced functional recovery [27]. Similarly, 
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Chen et al. in their study of 28 cases showed beneficial effects of OECs, SCs, or a 
combination of them in SCI [28].
Multipotent adult stem cells are safe to use clinically and have demonstrated 
improved neurological outcome.
5.2.3 Routes of transplantation
Several comparative studies have been carried out to determine the optimum 
route of administration. Geffner et al. reported administration of BMSCs intra-
venous, into the spinal canal and into the spinal cord to be safe and feasible. They 
also demonstrated improved ASIA, Barthel Index. Ashworth and Frenkel scores 
suggesting improved quality of life in most patients [14]. While intra-arterial 
transplantation of autologous bone marrow stem cells showed more improve-
ments as compared with that of intravenous route, intravenous transplantation 
showed better neurological outcome as compared to the site of injury [31–33]. 
Systemic routes show considerable dilution of cells at various cells like kidneys, 
liver, spleen and lungs. Several intraspinal approaches like intraparenchymal, 
intralesional and intramedullary approaches have been explored. Although 
no serious adverse events were noted; some patients complained of transient 
increase in paresthesia and muscle cramps. Intraspinal approaches are associated 
with increased risk of procedure related adverse effect due to invasive nature 
of the procedure [86–88]. Saito et al. [89], Pal et al. [90] and Kumar et al. [91] 
reported intrathecal administration to be the optimum route of administration. 
Although in this approach cells are transplanted away from the lesion area, MRI 
studies of radiolabeled cells have shown successful homing of cells at the site of 
injury [92].
6. Published clinical results of NeuroGen Brain and Spine Institute
6.1 Our protocol
6.1.1 Pre-intervention protocol
All the patients are thoroughly assessed clinically to rule out presence of active 
infections, HIV or HBsAg positive status and malignancies. Routine serological 
tests and chest X-ray are performed to ensure medical fitness. Neuroimaging using 
functional MRI brain and MRI of spine is performed. Various clinical outcome 
measures are marked before procedure assessing muscle tone, strength, ambula-
tion and sensations. Granulocyte colony stimulating factor injections are given 48 
and 24 h prior to the transplantation to enhance proliferation of cells in the bone 
marrow.
6.1.2 Intervention protocol
Our protocol has been designed after careful review of available literature. The 
protocol for harvesting and transplanting the cells is minimally invasive with no 
major adverse effects. It consists of three steps.
6.1.2.1 Aspiration of bone marrow
80–120 ml of bone marrow is aspirated from anterior superior iliac spine 
(Figure 3).
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6.1.2.2 Separation of BMMNCs
Density gradient method is used to separate the bone marrow mononuclear cell 
fraction which is then analyzed under microscope using Trypan blue to check for 
viability of the mononuclear cells. FACS analysis is used to identify CD34+ cells and 
viability, cell count and percentage of CD34+ cells are calculated (Figure 4).
6.1.2.3 Injection
Separated cell fraction is transplanted intrathecally in the space between L4 and 
L5 lumbar vertebrae by lumbar puncture. This is performed under local anesthesia 






Mechanism of action of stem cells for the treatment of spinal cord injury.
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6.1.3 Post intervention protocol
After the cell transplantation a home program of rigorous rehabilitation is 
prescribed Many of the patients show deficiencies due to prolonged immobility 
and poor nutrition, therefore nutritional supplements are prescribed as and when 
required. Patients are regularly followed up every 3 months.
6.1.4 Rationale for the protocol
Autologous cells are used to reduce the risk of immune rejection. Bone marrow 
mononuclear cells (BMMNCs) fraction consists of various cells types including 
mesenchymal cells, hematopoietic progenitor cells, side population cells, stromal 
cells and very small embryonic like cells. BMMNCs have demonstrated neurogenic 
potential and exhibit various paracrine effects like angiogenesis, upregulation of 
anti-inflammatory cytokines, secreting neurotrophic factors and growth factors, 
bring about immune modulation and stimulate resident stem cells. While the less 
invasive systemic routes, lead to dilution of the cells reaching the target organ, due 
to filtration of cells in various organs like liver, spleen, kidneys and lungs; more 
invasive routes like intra-spinal routes pose risk of procedure related adverse effect. 
Intra-thecal delivery therefore ensures delivery of maximum cells at the site of the 
injury with relatively reduced risk of procedure related adverse effects.
6.1.4.1 Role of rehabilitation
It is important that regenerative therapies are complimented with rehabilitative 
therapies like physiotherapy, occupational therapy, aquatic therapy, speech therapy, 
psychological intervention and nutritional advice. Regular goal-oriented rehabili-
tation provides neuroprotective, my protective, anti-inflammatory, antioxidant 
and neoangiogenic effects on a systemic level which resonate with the paracrine 
effects of cell therapy and compliment the effect of cell therapy. It is also believed 
that exercise can contribute to sub-granular and sub-ventricular neurogenesis. 
Neurogenesis consists of various processes. While differentiation, migration and 
axonal guidance are independent of physical activity synaptic pruning and plastic-
ity is dependent of physical activity and therefore rehabilitation plays a pivotal role 
in enhancing this. Therefore, we prescribe a regime of multidisciplinary rehabilita-
tion to be followed at home after the cell transplantation (Figure 2).
6.1.5 Adverse effects
This protocol is safe without any major adverse effects. We have so far treated 
more than 800 patients with spinal cord injury and none of the patients have 
exhibited any major irreversible adverse effects. A small percentage of patients have 
shown some minor procedure related adverse effects in SCI which are headache, 
pain at the site of injection, nausea and vomiting. These are usually self-limiting or 
can be completely relieved with minor medical intervention.
6.2 Published results
6.2.1 Thoracolumbar spinal cord injury
A detailed analysis of chronic thoracolumbar SCI patients who underwent 
intrathecal administration of autologous bone marrow mononuclear cells fol-
lowed by neurorehabilitation was conducted [84]. The study sample included 110 
thoracolumbar SCI patients. The outcome was recorded at a mean follow up of 
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2 years ± 1 month. The outcome measures were functional independence mea-
sure (FIM) score, American Spinal Injury Association scale (ASIA) and detailed 
neurological assessment. Data were statistically analyzed using McNemar’s Test to 
establish significance between the change in symptoms and the intervention.
A total of 100 out of 110 (91%) patients showed improvements. Improvement 
in trunk control was observed in 95.6% cases, bladder management in 33% with 
respect to shift from indwelling and condom catheter to self-intermittent catheter-
ization, partial sensory recovery in 27% and reduction of spasticity in 26%. All the 
patients showed improvement in postural hypotension. 38% wheelchair bound 
patients started walking with assistance. Functionally, 27% showed improved 
activities of daily living (ADLs) and 53.6% showed a positive change in FIM score. 
About 10% cases showed a shift in ASIA scale. A statistically significant association 
of these symptomatic improvements with the cell therapy intervention was estab-
lished using McNemar’s Test. On electrophysiological studies, 2 showed improve-
ment and 1 showed change in functional MRI [79] (Figure 6, Tables 1 and 2).
Table 1. 
Statistical significance for each symptomatic/functional change using McNemar’s test.
Figure 6. 
Symptomatic improvements in patients with spinal cord injury after stem cell therapy. The X-axis denotes 
symptoms presented in the patient population and the Y-axis denotes the number of patients. (ADLs—
activities of daily living) (Tables 1 and 2).
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6.2.2 Cervical SCI
A detailed analysis of chronic cervical SCI patients who underwent intrathecal 
administration of autologous bone marrow mononuclear cells followed by neurore-
habilitation was conducted [85]. This study includes 50 patients of chronic cervical 
SCI. The outcome was recorded at a mean follow up of 2 years ± 1 month. The 
outcome measures were functional independence measure (FIM) score, American 
Spinal Injury Association scale (ASIA) and detailed neurological assessment. Data 
were  statistically analyzed using McNemar’s Test to establish significance between the 
change in symptoms and the intervention. 37 out of 50 (74%) showed improvements. 
Sensation recovery was observed in 26% cases, improved trunk control in 22.4%, 
spasticity reduction in 20% and bladder sensation recovery in 14.2%. All the 50 cases 
had improvement in postural hypotension. 12.24% wheelchair bound patients started 
walking with assistance. Functionally, 20.4% patients showed improved ADLs and 
48% showed a positive change in FIM score. 6% cases showed a shift in ASIA scale. A 
statistical analysis using McNemar’s test established a significant association of these 
symptoms with the intervention [89]. No major side effects were noted in the dura-
tion of 2 years in both the studies. A better outcome was observed in thoracolumbar 
injury as compared to the cervical injury suggesting that the level of SCI greatly influ-
ences the recovery of the patient (Tables 3–5). Both studies demonstrated statistically 
significant clinical and functional outcome (Figure 7).
Table 2. 
Objective improvements evident on electromyography (A) and functional magnetic resonance imaging  
(B) after stem cell therapy in selected patients.
Table 3. 
McNemar’s test: table demonstrating the statistical analysis for each symptomatic improvement in cervical SCI 
using McNemar’s test.
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Table 5. 
Comparison between cervical SCI and thoracolumbar SCI: table comparing the outcome of cell transplantation 
in cervical SCI and thoracolumbar SCI.
Figure 7. 
Graph demonstrating symptomatic improvements in chronic cervical SCI patients after cell therapy.
Table 4. 
Percentage analysis of improvements: table demonstrating a detailed analysis of various factors and the 
improvements.
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6.2.3 Objective assessment using neuroimaging
A case study of a 32-year-old man with chronic thoracic complete spinal cord 
injury treated with intrathecal administration of autologous bone marrow mono-
nuclear cells with standard rigorous neurorehabilitation showed improved clinical 
outcome without any adverse effect [93]. Follow up assessment conducted at 3- and 
7-months post treatment showed improvements in motor activities, ambulation, 
bed mobilities, transfers and bladder management. Spinal cord independence 
measure (SCIM) improved from 27 to 64/100 and functional improvement measure 
(FIM) improved from 64 to 83 suggesting significant functional gain.
Brain functional magnetic resonance imaging (fMRI) shows patterns of cortical 
activation in response to attempted motor task. In chronic spinal cord injury cortico-
spinal tract neurons undergo retrograde degeneration. Therefore, the activation of 
the cortical areas is reduced in response to injury. Brain fMRI can thus be used to 
assess the outcome of the therapy. Post treatment fMRI in these patients showed 
activation of multiple regions in the sensory and associated areas, which was absent 
pre-treatment providing evidence for improved neural activation (Figure 8).
6.3 Unpublished data
We analyzed 300 patients with chronic thoracic and cervical spinal cord 
injury and noted that 96.2% of the patients showed clinical improvements. The 
improvements were classified as mild, moderate or significant based on how many 
Figure 8. 
fMRI images showing improved activation of sensorimotor and associated areas post transplantation.
Figure 9. 
Clinical outcome in patients with SCI post cell treatment.
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symptoms showed improvements (3 symptoms—mild improvement, 4–6 symp-
toms—moderate improvement and more than 6 symptoms—significant improve-
ment) majority of the patients showed moderate improvements (Figure 9).
Symptomatic analysis of these patients showed reduction in spasticity, 
sensory motor recovery, recovery of bladder sensation, increased functional 
independence while performing ADLS, improved balance and ambulation 
(Figure 10).
7. Limitations and future directions
Currently little objective evidence is available to show the regeneration of spinal 
cord and increased connectivity of spinal tracts. Enhanced radio imaging tools are 
required for better visualization of the outcome.
Although various cells and routes of administration have been explored an 
optimum cell type and route of administration remain elusive due to heterogeneity 
of research protocols, sample size, treatment regimen and lack of multi-centric 
high-quality studies. Comparison between different protocols is required to be car-
ried out using rigorous methodology to identify an optimum clinical protocol that 
yields maximum recovery.
It takes about 6 months to generate iPSCs from autologous somatic cells and 
almost a year to test the safety of cells for transplantation, this combines with risks 
associated with iPSCs including genetic and epigenetic abnormalities, tumorigenic-
ity and immunogenicity related to cell trans-plantation has prevented their clinical 
translation so far [94–96]. Advent in iPSC technology and its clinical translation is 
the future direction for medical sciences.
8. Conclusion
Spinal cord injury is a devastating and disabling neurological disorder with no 
definite cure. Several treatment strategies are being explored for improved clinical 
Figure 10. 
Symptomatic improvements in patients with SCI post cell therapy.
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outcome especially for chronic injuries. Stem cell therapy is a promising treat-
ment modality. Use of stem cells for the treatment of spinal cord injury is safe and 
improves neurological as well as functional outcome. With the available evidence 
autologous multipotent stem cells like bone marrow derived mononuclear cells 
show positive clinical outcomes with no adverse effects. Factors like level of injury, 
time since injury, concomitant disorders and rigor of neurorehabilitation can influ-
ence the outcome of the cell treatment.
Lot of evidence has been generated over the last decade demonstrating the 
benefits of using stem cells to improve sensory-motor function, functional inde-
pendence of the patients and quality of life. Stem cell therapy helps to reduce the 
complications post spinal cord injury due to their positive effect. Although it does 
not provide a complete cure at the moment, it certainly holds the potential to 
improve functional independence and quality of life. It is important to supplement 
stem cell therapy with current treatments and rehabilitation for optimum clinical 
improvement.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
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